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We studied the levels of matrix metalloproteinase (MMP)-2, membrane-type (MT)1-MMP, MT2-MMP, and MT3-MMP in 43 malignant pleural and peritoneal effusions using reverse transcription-polymerase chain reaction (RT-PCR) and cellular localization of MT1-MMP in 66 effusion specimens and 85 corresponding primary and metastatic tumors using messenger RNA (mRNA) in situ hybridization (ISH). In 43 effusions, MMP-2 mRNA was detected in 37, MT1-MMP in 25, and MT2-MMP in 32. Expression of MT1-MMP and MT2-MMP was found in 21 specimens; in 16 MT-MMP-positive specimens, mRNA for only 1 of 2 enzymes was expressed. MT3-MMP mRNA was not detected. High levels of MMP-2 mRNA were detected more often in effusions with high MT1-MMP and/or MT2-MMP mRNA expression. Using ISH, MT1-MMP mRNA was localized to cancer cells in 27 of 58 malignant effusions; focal signals were detected in mesothelial cells in 7 of 42. MT1-MMP was localized to tumor cells in 32 of 85 primary and metastatic solid lesions, and stromal cells expressed MT1-MMP in 3. Tumor cell MT1-MMP expression in effusion specimens did not differ from primary or metastatic lesions. MT-MMP expression in tumor cells in effusions showed no association with effusion site or tumor type using ISH and RT-PCR.
Matrix metalloproteinases (MMPs) are a family of zincdependent proteolytic enzymes with a central role in extracellular matrix (ECM) remodeling in a variety of physiologic and pathologic conditions. 1 In addition to their role in ECM degradation, MMPs seem to be involved in complex interactions with other cellular and extracellular proteins, thereby assuming an important role in normal cellular function, as well as in tumor invasion and metastasis. 2 Membrane-type (MT) MMPs contain propeptide, catalytic, and hemopexinlike domains, as do other MMPs, but contain an additional transmembrane domain, as well as a cytoplasmic tail at the Cterminus. 3, 4 MT-MMPs are activated intracellularly by furin or related enzymes, as well as extracellularly by plasmin. 3, 4 Six MT-MMPs have been identified, with a different distribution in normal and neoplastic tissues. [5] [6] [7] [8] [9] [10] MT1-MMP, MT2-MMP, MT3-MMP, and MT5-MMP share about 50% structural homology, whereas MT4-MMP and MT6-MMP may represent a new subgroup of MT-MMPs, characterized by absence of the aforementioned cytoplasmic tail. 10 MT-MMPs (with the exclusion of MT4-MMP) activate MMP-2 (gelatinase A), an enzyme that has a key role in local invasion and dissemination of a large variety of tumors, 3,4,11-12 through a 2-step cleavage reaction, following the formation of a membrane complex with MMP-2 and tissue inhibitor of metalloproteinase-2. 12 The efficiency in mediating this reaction seems to be highest for MT1-MMP, followed by MT3-MMP, and is lower for MT2-MMP. 3 MT1-MMP also can activate procollagenase-3 (MMP-13), while recombinant forms of all 3 enzymes can cleave a large number of ECM proteins. 3 Carcinoma of the ovary continues to be the major cause of mortality due to gynecologic cancer in the Western countries, with a 5-year survival rate of 35%. 13 As manifested by their frequent diagnosis at an advanced stage, these tumors tend to spread widely within the peritoneal cavity, often resulting in the accumulation of ascitic fluid, and occasionally to distant organs. 14 The presence of MMPs in ovarian neoplasia and their contribution to the invasive phenotype of these tumors has been demonstrated in in vitro studies, as well as in studies of clinical specimens (reviewed by Stack et al 15 ). The presence of MT1-MMP in ovarian carcinoma cells, 16, 17 as well as in peritumoral stromal cells 17 was demonstrated in 2 studies, using immunohistochemistry 16 and messenger RNA (mRNA) in situ hybridization. 17 MMP-2 was localized to the same cell populations in both studies. However, the relative expression of MT1-MMP in effusion specimens in comparison with primary and metastatic tumors has not been studied, nor has the expression of MT2-MMP and MT3-MMP in ovarian carcinoma. Thus, the object of the present study was to study mRNA expression of MT1-MMP, MT2-MMP, and MT3-MMP in serous effusions of patients diagnosed with ovarian carcinoma. In addition, we attempted to locate the cellular source of MT1-MMP and to compare the expression of this enzyme in carcinoma cells in pleural and peritoneal effusions with that of the corresponding primary tumors and metastatic lesions.
Materials and Methods
Effusion Specimen Protocol
Fresh, nonfixed peritoneal and pleural effusions (volume range, 20-2,000 mL) were submitted to the Division of Cytopathology, Department of Pathology, the Norwegian Radium Hospital, Oslo, during the period January 1998 through March 1999. Effusion specimens, as well as relevant clinical data, were obtained from the Department of Gynecologic Oncology, Norwegian Radium Hospital. Specimens were centrifuged in an Eppendorf 5810 centrifuge (Eppendorf, Hamburg, Germany) for 10 minutes at 2,000 rpm. The resulting pellet was used for the preparation of 4 cytologic smears (2 alcohol-fixed, Papanicolaou-stained and 2 airdried, rapid Romanowsky-stained smears) and a formalinfixed, paraffin-embedded cell block. The remaining material was frozen in RPMI and dimethyl sulfoxide medium. Cell blocks were prepared using the Shandon Lipshaw Cytoblock kit (Shandon, Pittsburgh, PA).
Morphologic Examination
Cytologic smears from all samples were evaluated by a senior cytopathologist (A.B. or B.R.) and reported as positive, suggestive of carcinoma, or negative for malignant cells. Owing to the possibility of sampling a different population in cell blocks, sections from all cell blocks were evaluated in a double-blind manner and graded as described by 2 senior cytopathologists (A.B. and B.R.). The diagnostic criteria used were consistent with established guidelines. 18 Cell block sections subsequently were stained using monoclonal antibodies directed against epithelial markers to confirm the morphologic diagnosis, as previously described. 19 
Reverse Transcription-Polymerase Chain Reaction
We analyzed 43 malignant effusions for the presence of MMP-2, MT1-MMP, MT2-MMP, and MT3-MMP. The distribution of the studied specimens according to histologic type and location is given in ❚Table 1❚. All specimens contained a distinct population of carcinoma cells. Specimens were defined as pure when the tumor cell population consisted of more than 80% of the total cell population (23 samples). Mixed effusions (20 samples) consisted of an inflammatory or mesothelial component exceeding 20% of the total cell population.
Polymerase chain reaction (PCR) analysis was performed on reversed transcribed mRNA using the primers listed in ❚Table 2❚. Products were separated on 1% agarose gels. The HT-1080 fibrosarcoma cell line was used as the control in all reactions. Band size was evaluated by using the MMP/glyceraldehyde-3-phosphate dehydrogenase ratio.
mRNA In Situ Hybridization
Effusion Specimens
The studied material consisted of 58 malignant effusion specimens, obtained preoperatively, intraoperatively, or at disease recurrence, from 50 patients diagnosed with ovarian carcinoma and 3 patients diagnosed with primary peritoneal carcinoma. These consisted of 44 peritoneal and 14 pleural effusions. Eight reactive effusions, obtained from patients with various malignant neoplasms or a clinical suspicion of malignant neoplasm, also were studied (total, 66 effusion specimens). The distribution of the studied malignant effusions according to histologic type and site is given in ❚Table 3❚.
Tumor Specimens
Eighty-five archival surgical specimens, consisting of primary tumors (n = 36) and metastatic lesions (n = 49) from the aforementioned patients, also were studied. Formalinfixed, paraffin-embedded tissue blocks were obtained from archival material in the Department of Pathology, the Norwegian Radium Hospital, or from other hospitals in Norway. All tissue specimens underwent microscopic confirmation of diagnosis, tumor type, and histologic grade, according to established criteria. 20 Tumor distribution according to histologic type and biopsy site is shown in ❚Table 4❚.
Tissue sections (4-µm-thick) of formalin-fixed, paraffinembedded specimens were mounted on silane-coated slides. Sectioning was performed in ribonuclease-free water. Slides were dewaxed and rehydrated using xylenes (twice, 10 minutes each time) and isopropyl alcohol (5 minutes). Hybridization using the MT1-MMP probe was performed as previously described. 21 Hybridization results were interpreted as absent, weak, or intense. Strong, dark blue staining was interpreted as intense. Labeling of fewer than 20% of the cells was defined as focal, while labeling of 20% or more was interpreted as diffuse. A minimum of 300 cells, when present, were evaluated.
Statistical Analysis
Statistical analysis of MT1-MMP in situ hybridization results consisted of the following comparative analyses: (1) in situ hybridization results in malignant epithelial vs reactive mesothelial cells in effusion specimens; (2) signed rank test. In cases for which more than one metastatic lesion was available, the lesion showing the most intense staining was included in the statistical evaluation. (Table 6 ). Carcinoma cells in 6 tumors showed an intense signal, but the signal was not observed in stromal cells. The differences in MT1-MMP expression between tumor and stromal cells were statistically significant in primary (P = .001) and metastatic (P = .002) lesions.
Results
Reverse
Comparison of tumor cell expression in effusions with surgical specimens of both primary and metastatic lesions did not reveal significant differences (P > .05).
Discussion
The role of MT-MMPs in the activation of MMPs has been shown in vitro and in vivo, best documented for MT1-MMP-mediated activation of MMP-2. 22 MT1-MMP was localized to tumor and/or stromal cells in various malignant tumors, including carcinomas of the ovary, 16, 17 pancreas, 23 bladder, 24 head and neck, 25 liver, 26 uterine cervix, 21, 27 stomach, 28 colon, 25 breast, 25, 29 and lung. 29 However, fewer studies investigated the expression of other MT-MMPs in epithelial tumors. [30] [31] [32] These studies evaluated thyroid, 30 breast, 31 and urinary bladder 32 carcinomas. While MT1-MMP and MT2-MMP were detected in carcinoma cells of all the aforementioned tumor types, MT3-MMP was undetectable in thyroid and breast carcinomas and was faintly detectable in benign bladder mucosa and bladder carcinomas. [30] [31] [32] The present study analyzed mRNA expression of MMP-2, MT1-MMP, MT2-MMP, and MT3-MMP in serous effusions of patients with ovarian carcinoma using RT-PCR, with subsequent evaluation of MT1-MMP expression in effusions and primary and metastatic lesions using mRNA in situ hybridization.
Our results agree with the aforementioned reports, as MT3-MMP mRNA was not detected in any of our samples. 16 pointing to the central role of MMP-2 in ovarian carcinoma, as well as with recent findings (Davidson, Reich, Berner, et al, unpublished data, 2000) in a study using immunohistochemistry and mRNA in situ hybridization that demonstrated up-regulation of MMP-2 in ovarian carcinoma cells on protein and mRNA levels compared with primary ovarian carcinomas, with a concomitant decrease in MMP-9 protein levels. MMP-2 was colocalized to carcinoma and mesothelial cells. However, expression in the tumor cell population predominated (Davidson, Reich, Berner, et al, unpublished data, 2000) . In the present study, 37 of 43 specimens, both pure and mixed effusions, expressed MMP-2. Production of this enzyme by both cell populations thus may enhance ECM degradation of peritoneal tissues, possibly facilitating cancer cell invasion of abdominal structures, a characteristic of tumor spread in ovarian carcinoma. The association of MT1-MMP and MT2-MMP mRNA with high levels of MMP-2 mRNA suggests that both enzymes may have a role in the activation of MMP-2 in serous effusions.
Limited data are available about the relative contribution of carcinoma cells and peritumoral stromal cells or mesothelial cells to MT1-MMP production in ovarian carcinoma. MT1-MMP mRNA has been localized to stromal cells and tumor cells in a study that included 19 invasive carcinomas, most often to stromal cells (18/ 19 vs 8/19 cases) . 17 In an additional study of various carcinomas, including 4 of ovarian origin, MT1-MMP protein expression was detected in carcinoma and stromal cells in all cases. 33 MT1-MMP has been localized immunohistochemically to carcinoma cells in short-term cultures of ascitic specimens. 16 However, mesothelial cell expression has not been studied previously. This issue became more intriguing in view of the relatively high expression of MT1-MMP in malignant effusions with substantial reactive (inflammatory or mesothelial) populations. We detected a consistently predominant MT1-MMP mRNA expression in carcinoma cells and a negligible one in stromal cells. This finding was valid for primary and metastatic tumors and was reproduced in effusion specimens when carcinoma cells were compared with reactive mesothelial cells. Inflammatory cells in mixed effusions were similarly negative. Concomitantly, carcinoma cells in primary tumors and metastatic lesions and effusions showed a comparable profile. The finding of MT1-MMP in carcinoma cells is in agreement with the findings of Fishman et al 16 using short-term cultures of ascites specimens. The discrepancy between our results and those of Afzal and coworkers 17 can possibly result from the use of different sensitivity of the detection systems. In addition, different tumors were studied in the 2 studies. Eight serous and 11 nonserous tumors were included in the study by Afzal and coworkers, while 47 of 58 effusions and 70 of 85 solid lesions of the serous type were included in our study.
The detection of metastatic ovarian carcinoma cells in pleural effusion specimens defines a stage IV disease irrespective of the presence or absence of solid metastases in distant organs and is associated with an unfavorable outcome. 34 In contrast, the dissemination of ovarian carcinoma cells within the peritoneal cavity is postulated to be initiated by direct shedding from the surface of the ovary and may occur in localized tumors, ie, FIGO (International Federation of Gynecology and Obstetrics) stage Ic. This division into 2 apparently nonoverlapping pathogenic mechanisms is not supported by the reports associating the presence of large-volume ascites 35, 36 and positive peritoneal cytology 36 with poor outcome in ovarian carcinoma, unless one assumes that cells with markedly variable metastatic properties are found in peritoneal effusions. Although MMP-2 mRNA expression was detected more often in pleural effusions, the resemblance to the MT-MMP expression profile, using RT-PCR and in situ hybridization, provides further evidence that ovarian carcinoma cells in peritoneal and pleural fluids do not differ significantly from each other in their protease phenotype. These results are also in agreement with recent reports, in which both carbohydrate antigen expression 37 and E-cadherin complex expression 38 were similar for metastatic carcinoma cells in both compartments. Considered together, it seems that further studies are necessary to determine the genotypic and phenotypic alterations, if any, that are involved in the transition from stage III to stage IV disease in ovarian carcinomas. Expression of MMP-2, MT1-MMP, MT2-MMP, and MT3-MMP mRNA was studied in serous effusions from patients diagnosed with ovarian carcinoma, with further characterization of MT1-MMP expression in corresponding primary and metastatic lesions. The data presented suggest a positive correlation between MMP-2, MT1-MMP, and MT2-MMP mRNA expression and, possibly, a role in ovarian carcinoma pathogenesis, mainly through tumor cell production of these enzymes.
